356 related articles for article (PubMed ID: 29223454)
1. Preparation, characterization and immunological evaluation of alginate nanoparticles loaded with whole inactivated influenza virus: Dry powder formulation for nasal immunization in rabbits.
Dehghan S; Kheiri MT; Abnous K; Eskandari M; Tafaghodi M
Microb Pathog; 2018 Feb; 115():74-85. PubMed ID: 29223454
[TBL] [Abstract][Full Text] [Related]
2. Rabbit nasal immunization against influenza by dry-powder form of chitosan nanospheres encapsulated with influenza whole virus and adjuvants.
Dehghan S; Tafaghodi M; Bolourieh T; Mazaheri V; Torabi A; Abnous K; Tavassoti Kheiri M
Int J Pharm; 2014 Nov; 475(1-2):1-8. PubMed ID: 25148732
[TBL] [Abstract][Full Text] [Related]
3. Characterization of Immune Responses to an Inactivated Avian Influenza Virus Vaccine Adjuvanted with Nanoparticles Containing CpG ODN.
Singh SM; Alkie TN; Abdelaziz KT; Hodgins DC; Novy A; Nagy É; Sharif S
Viral Immunol; 2016 Jun; 29(5):269-75. PubMed ID: 27077969
[TBL] [Abstract][Full Text] [Related]
4. Characterization of immunogenicity of avian influenza antigens encapsulated in PLGA nanoparticles following mucosal and subcutaneous delivery in chickens.
Alkie TN; Yitbarek A; Taha-Abdelaziz K; Astill J; Sharif S
PLoS One; 2018; 13(11):e0206324. PubMed ID: 30383798
[TBL] [Abstract][Full Text] [Related]
5. Development and characterization of chitosan coated poly-(ɛ-caprolactone) nanoparticulate system for effective immunization against influenza.
Gupta NK; Tomar P; Sharma V; Dixit VK
Vaccine; 2011 Nov; 29(48):9026-37. PubMed ID: 21939718
[TBL] [Abstract][Full Text] [Related]
6. Induction of systemic and mucosal immune responses by intranasal administration of alginate microspheres encapsulated with tetanus toxoid and CpG-ODN.
Tafaghodi M; Sajadi Tabassi SA; Jaafari MR
Int J Pharm; 2006 Aug; 319(1-2):37-43. PubMed ID: 16701972
[TBL] [Abstract][Full Text] [Related]
7. Novel dry powder preparations of whole inactivated influenza virus for nasal vaccination.
Garmise RJ; Staats HF; Hickey AJ
AAPS PharmSciTech; 2007 Oct; 8(4):E81. PubMed ID: 18181542
[TBL] [Abstract][Full Text] [Related]
8. Delivery of an inactivated avian influenza virus vaccine adjuvanted with poly(D,L-lactic-co-glycolic acid) encapsulated CpG ODN induces protective immune responses in chickens.
Singh SM; Alkie TN; Nagy É; Kulkarni RR; Hodgins DC; Sharif S
Vaccine; 2016 Sep; 34(40):4807-13. PubMed ID: 27543454
[TBL] [Abstract][Full Text] [Related]
9. CpG ODN G9.1 as a novel nasal ODN adjuvant elicits complete protection from influenza virus infection without causing inflammatory immune responses.
Tateishi K; Fujihashi K; Yamamoto N; Hasegawa H; Ainai A; Sato K; Iho S; Yamamoto S; Maeyama JI; Odagiri T; Asanuma H
Vaccine; 2019 Aug; 37(36):5382-5389. PubMed ID: 31345642
[TBL] [Abstract][Full Text] [Related]
10. Preparation and in vivo study of dry powder microspheres for nasal immunization.
Tafaghodi M; Rastegar S
J Drug Target; 2010 Apr; 18(3):235-42. PubMed ID: 19929307
[TBL] [Abstract][Full Text] [Related]
11. Long-lasting protective immunity against H7N9 infection is induced by intramuscular or CpG-adjuvanted intranasal immunization with the split H7N9 vaccine.
Zhou Y; Li S; Bi S; Li N; Bi Y; Liu W; Wang B
Int Immunopharmacol; 2020 Jan; 78():106013. PubMed ID: 31806571
[TBL] [Abstract][Full Text] [Related]
12. Development of a novel adjuvanted nasal vaccine: C48/80 associated with chitosan nanoparticles as a path to enhance mucosal immunity.
Bento D; Staats HF; Gonçalves T; Borges O
Eur J Pharm Biopharm; 2015 Jun; 93():149-64. PubMed ID: 25818119
[TBL] [Abstract][Full Text] [Related]
13. Development and characterization of a new carrier for vaccine delivery based on calcium-alginate nanoparticles: Safe immunoprotective approach against scorpion envenoming.
Nait Mohamed FA; Laraba-Djebari F
Vaccine; 2016 May; 34(24):2692-9. PubMed ID: 27109567
[TBL] [Abstract][Full Text] [Related]
14. Comparison of adjuvants for a spray freeze-dried whole inactivated virus influenza vaccine for pulmonary administration.
Patil HP; Murugappan S; de Vries-Idema J; Meijerhof T; de Haan A; Frijlink HW; Wilschut J; Hinrichs WL; Huckriede A
Eur J Pharm Biopharm; 2015 Jun; 93():231-41. PubMed ID: 25896446
[TBL] [Abstract][Full Text] [Related]
15. Combined Intranasal Nanoemulsion and RIG-I Activating RNA Adjuvants Enhance Mucosal, Humoral, and Cellular Immunity to Influenza Virus.
Wong PT; Goff PH; Sun RJ; Ruge MJ; Ermler ME; Sebring A; O'Konek JJ; Landers JJ; Janczak KW; Sun W; Baker JR
Mol Pharm; 2021 Feb; 18(2):679-698. PubMed ID: 32491861
[TBL] [Abstract][Full Text] [Related]
16. Examination of the effects of virus inactivation methods on the induction of antibody- and cell-mediated immune responses against whole inactivated H9N2 avian influenza virus vaccines in chickens.
Astill J; Alkie T; Yitbarek A; Taha-Abdelaziz K; Bavananthasivam J; Nagy É; Petrik JJ; Sharif S
Vaccine; 2018 Jun; 36(27):3908-3916. PubMed ID: 29853199
[TBL] [Abstract][Full Text] [Related]
17. Evaluation of CpG-ODN-adjuvanted polyanhydride-based intranasal influenza nanovaccine in pigs.
Dhakal S; Ghimire S; Renu S; Ross KA; Lakshmanappa YS; Hogshead BT; Bernardo P; Lee CW; Wannemuehler MJ; Narasimhan B; Renukaradhya GJ
Vet Microbiol; 2019 Oct; 237():108401. PubMed ID: 31585639
[TBL] [Abstract][Full Text] [Related]
18. Alginate coated chitosan nanoparticles are an effective subcutaneous adjuvant for hepatitis B surface antigen.
Borges O; Silva M; de Sousa A; Borchard G; Junginger HE; Cordeiro-da-Silva A
Int Immunopharmacol; 2008 Dec; 8(13-14):1773-80. PubMed ID: 18801462
[TBL] [Abstract][Full Text] [Related]
19. A Comparison of Toll-Like Receptor 5 and 21 Ligands as Adjuvants for a Formaldehyde Inactivated H9N2 Avian Influenza Virus Vaccine in Chickens.
Astill J; Alkie T; Yitbarek A; Taha-Abdelaziz K; Shojadoost B; Petrik JJ; Nagy É; Sharif S
Viral Immunol; 2018 Nov; 31(9):605-612. PubMed ID: 30222508
[TBL] [Abstract][Full Text] [Related]
20. Bacterium-like particles supplemented with inactivated influenza antigen induce cross-protective influenza-specific antibody responses through intranasal administration.
de Haan A; Haijema BJ; Voorn P; Meijerhof T; van Roosmalen ML; Leenhouts K
Vaccine; 2012 Jul; 30(32):4884-91. PubMed ID: 22537989
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
